Aurobindo Pharma
NSEI:AUROPHARMA Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 38 Fair Values set on narratives written by author
WA
Consensus Narrative from 28 Analysts
Penicillin G Ramp-Up And Biosimilar Breakthroughs To Propel Revenue Growth And Boost Net Margins
Key Takeaways Strategic focus on new product launches and U.S. pricing stability can drive revenue growth while improving EBITDA margins. Expansion in biosimilars and peptides, alongside operational efficiencies, is expected to enhance net margins and long-term growth.
View narrative₹1.54k
FV
27.4% undervalued intrinsic discount8.74%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
24 days ago author updated this narrative